Navigation Links
Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:11/6/2008

DALLAS, Nov. 6 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that it will make a presentation at the Rodman & Renshaw Annual Global Investment Conference to be held November 10-12, 2008 at the New York Palace Hotel. Jeffrey B. Davis, CEO of Access is scheduled to speak on Tuesday, November 11, 2008 at 2:50 p.m. Eastern Time, and will give a corporate overview and discuss the Company's product opportunities.

The presentation will be available via webcast and can be accessed at: http://www.wsw.com/webcast/rrshq14/accp.ob. The replay can be obtained at the same link for 90 days.

About ProLindac(TM):

ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include Prodac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeuti
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. Mymetics Corporation Information to be Available Through Standard & Poors Market Access Program
4. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
5. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
6. NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population
7. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
10. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
11. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... Increasing its efforts to resolve the GMO Controversy , ... The GMO TRUTH podcast on both ITunes and at The ... mission to discover the truth and change the world. ... truth about the GMOs in our food supply,” adds a ... an expansion of the documentary/investigative film-making methodology in place at ...
(Date:2/27/2015)... , Feb. 27, 2015 A ... the NCATS rare-diseases portfolio " in Science ... new financing technique to reduce the risk associated ... and potentially unlock new levels of funding for ... product of a unique collaboration between scientists at ...
(Date:2/27/2015)... Australia , Feb. 27, 2015 Bionomics ... from the DisrupTOR-1 trial of BNC105 in patients with ... in Orlando, Florida . The data ... of the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and ...
(Date:2/27/2015)... , Feb. 27, 2015  Steep Hill, the ... US and internationally, intends to open a full service ... New Mexico , bringing advanced scientific tools and ... Steep Hill is currently the only laboratory ... conduct potency and contaminant testing in order to meet ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2
... and WEYBRIDGE, England, Dec. 6, 2010 ViroPharma ... the global leader in developing long-term strategic solutions ... companies have partnered to facilitate access to certain ...  ViroPharma,s NPP, developed and managed by Idis, will ...
... Clarient, Inc. ("Clarient") (Nasdaq: CLRT ) announced today ... Crane Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of ... to acquire all of the outstanding shares of capital stock ... Offer from midnight, New York City time, at the end ...
... Institute (BRI), the research arm of Baylor Health Care ... with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly ... at the Baylor Institute for Immunology Research (BIIR), a ... BIIR,s leading position in human immunology with particular focus ...
Cached Biology Technology:ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program 2ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program 3Clarient Tender Offer Extended; Clarient Makes Additional Disclosures to Settle Litigation 2Clarient Tender Offer Extended; Clarient Makes Additional Disclosures to Settle Litigation 3Clarient Tender Offer Extended; Clarient Makes Additional Disclosures to Settle Litigation 4Roche, Baylor Research Institute Partner in Human Immunology Research 2
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... , January 28, 2015 ... Analysis, Size And Segment Forecasts To 2020 has Been ... IR camera market is expected to reach USD 5.10 ... Grand View Research, Inc. IR cameras help identify the ... are expected to witness surging demand in medical imaging ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition ... report to their offering. , The primary ... is who she/he is claiming to be, and for this ... physical characteristics, such as fingerprint, hand or palm print, iris, ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... January 28, 2014 Scientists at Harvard University ... of the natural nanoscale photonic device that enables a ... inspire improved protective camouflage for soldiers on the battlefield. ... sea," can rapidly alter both the color and pattern ...
... A University of Colorado Cancer Center study published today ... and Physics shows that patients taking crizotinib for ... use up to three courses of targeted radiation therapy ... of resistant disease allows patients to continue treating the ...
... advanceselectronic devices, the iPhone, medical implants, disease detection ... of revolutionary interfaces. The study of creating and ... engineeringis one of the most exciting research frontiers. ... of Engineering will welcome leading engineers, physicists, chemists, ...
Cached Biology News:'Chameleon of the sea' reveals its secrets 2'Chameleon of the sea' reveals its secrets 3'Weeding the garden' lets ALK+ lung cancer patients continue crizotinib 2'Weeding the garden' lets ALK+ lung cancer patients continue crizotinib 3Interfacing with the future 2
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
... technology incorporating the sophisticated DirectDrive architecture ... new Varian NMR System is undeniably ... ,The Varian NMR System features parallel ... channel, providing pulse sequence programming power ...
Biology Products: